Clinical trials: Cancer Progression
Osteoarthritis (OA) of the Knee
Effect of Steroid Injections in a Knee With Osteoarthritis
A steroid (triamcinolone) 40 mg will be compared to placebo in a randomized placebo-controlled clinical trial testing the effect of this steroid versus placebo given into the study knee joint that has osteoarthritis (OA).
- Trial name
- NCT01230424
- Testing
- Triamcinolone Acetonide
- Where
- 2 sites in United States
- Volunteers
- 140 people
- Sponsor
- Tufts Medical Center
NSCLC
Phase 1/2 Study of BBT-176 in Advanced NSCLC With Progression After EGFR TKI Treatment
This clinical trial is the first-in-human study of BBT-176. The purpose of this trial is to investigate the safety and tolerability of BBT-176 (Part 1) and to evaluate the anti-tumor activity of BBT-176 (Part 2).
- Trial name
- NCT04820023
- Testing
- BBT-176, QD, BBT-176, BID
- Where
- 4 sites in South Korea
- Volunteers
- 45 people
- Sponsor
- Bridge Biotherapeutics, Inc.
Gastrointestinal Stromal Tumors
Rechallenge of Imatinib in GIST Having no Effective Treatment: RIGHT
The objective of this study is to compare the clinical outcomes following resumption of dosing (re-challenge) with Imatinib plus best supportive care versus placebo plus best supportive care in patients with advanced/incurable…
- Trial name
- NCT01151852
- Testing
- Imatinib
- Where
- South Korea
- Volunteers
- 81 people
- Sponsor
- Asan Medical Center
Cancer
Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists
This study will examine the efficacy and safety of lapatinib in patients with ErbB2 positive ovarian, gastric/esophageal adenocarcinoma, uterine serous papillary, or bladder cancers.
- Trial name
- NCT00447226
- Where
- 20 sites in United States
- Volunteers
- 32 people
- Sponsor
- GlaxoSmithKline
Metastatic Renal Cell Carcinoma
A Study of Ramucirumab in Participants With Metastatic Renal Cell Carcinoma
The purpose of this study is to determine whether ramucirumab is effective treatment in participants with metastatic renal cell carcinoma who have developed progressive disease or become intolerant to tyrosine kinase inhibitor…
- Trial name
- NCT00515697
- Testing
- Ramucirumab
- Where
- 11 sites in United States
- Volunteers
- 39 people
- Sponsor
- Eli Lilly and Company
Coronary Atherosclerosis, Coronary Artery Calcification
Firefighter Aged Garlic Extract Investigation With CoQ10 as a Treatment for Heart Disease (FAITH)
1. Statement of Problem According to the National Fire Protection Association (NFPA), 43.7% of all firefighters that died on the job experienced sudden cardiac death. The job also affords an incredible amount of stress.
- Conditions
- Coronary Atherosclerosis, Coronary Artery Calcification, Coronary Stenosis
- Trial name
- NCT00860847
- Testing
- Aged garlic extract and Coenzyme Q10
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Myopia
Topical Application of Low-concentration (0.01%) Atropine on the Human Eye With Fast and Slow Myopia Progression Rate
Our project is a 24-month longitudinal randomized controlled trial that aims to investigate the myopia development after topical application of 0.01% atropine in children with either fast or slow myopia progression classified…
- Trial name
- NCT03374306
- Testing
- Atropine (0.01%), Artificial tear
- Where
- Hong Kong
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- The Hong Kong Polytechnic University
Leukemia, Myeloid, Acute
Study of Vosaroxin and Cytarabine for the Treatment of Adults 60 Years of Age or Older With Previously Untreated AML
This is a pilot efficacy assessment clinical trial of vosaroxin and cytarabine for the treatment of adults 60 years of age or older with previously untreated acute myeloid leukemia.
- Trial name
- NCT02485353
- Testing
- Vosaroxin and Cytarabine
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Hamid Sayar
Parkinson's Disease
Real-PD Trial: Development of Clinical Prognostic Models for Parkinson's Disease
Background: Long-term management of Parkinson's disease (PD) does not reach its full potential due to lack of knowledge about disease progression.
- Trial name
- NCT02474329
- Testing
- Clinical assessment, Fox Insight self-monitoring android app and falls detector
- Where
- Netherlands
- Volunteers
- 304 people
- Sponsor
- Radboud University Medical Center
Type 1 Diabetes, Preservation of Insulin Secretion
Canakinumab Study in Individuals With Newly Diagnosed Type 1 Diabetes
Canakinumab is a fully human anti-interleukin-1β (anti-IL-1β) monoclonal antibody (IgG-1 class). Canakinumab is designed to bind to human IL-1β and to functionally neutralize the bioactivity of this pro-inflammatory cytokine.
- Conditions
- Type 1 Diabetes, Preservation of Insulin Secretion, Newly Diagnosed Type 1 Diabetes, Canakinumab in Type 1 Diabetes
- Trial name
- TN14 (NCT00947427)
- Testing
- canakinumab (anti IL-1beta)
- Where
- 12 sites in United States, Canada
- Volunteers
- 71 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Prevention of Subclinical Atherosclerosis Progression, Prevention of Cognitive Decline
Nattokinase Atherothrombotic Prevention Study
The potential for nattokinase to "thin" blood and to reduce blood clotting by positive antithrombotic and fibrinolytic effects presents a unique opportunity to safely study such effects on cardiovascular disease and cognition.
- Trial name
- NAPS (NCT02080520)
- Testing
- Nattokinase
- Where
- United States
- Volunteers
- 265 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Parkinson's Disease
Imaging Biomarkers of Progression of Mobility Impairment in Parkinson Disease
The purpose of this research is to evaluate changes in cholinergic brain activity over time in subjects with Parkinson disease.
- Trial name
- NCT01106976
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Uterine Cervical Neoplasms
Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer
The main purpose of this study was to evaluate clinical efficacy and safety of bintrafusp alfa in participants with advanced, unresectable cervical cancer with disease progression during or after platinum-containing chemotherapy.
- Trial name
- NCT04246489
- Testing
- Bintrafusp alfa
- Where
- 73 sites in United States, Argentina and 10 more
- Volunteers
- 146 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Arterial Stiffness, Vitamin K2 Deficiency
Vitamin K2 Supplementation and Arterial Stiffness in the Renal Transplant Population (The KING Trial)
This study is a single arm, single center clinical trial that aims to evaluate the effect of 8 weeks of vitamin K2 replacement (360 mcg/day) on the progression of arterial stiffness in stable renal transplant patients.
- Trial name
- KING (NCT02517580)
- Testing
- Vitamin K2 (MK7)
- Where
- Lebanon
- Volunteers
- 60 people
- Sponsor
- Lebanese American University
Colorectal Neoplasms
Phase 2 Study With Abraxane (Nab®Paclitaxel) in Metastatic Colorectal Cancer
The purpose of this study is to evaluate the safety and efficacy of Abraxane (nab-paclitaxel) in subjects with previously treated metastatic colorectal cancer.
- Trial name
- NCT02103062
- Testing
- ABI-007
- Where
- 6 sites in France
- Volunteers
- 41 people
- Sponsor
- Celgene
Non-small Cell Lung Cancer Metastatic
A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Unresectable Advanced and/or Metastatic Non-Small Cell Lung Cancer
This single arm study will assess the efficacy and safety of erlotinib + gemcitabine in chemotherapy-naive participants with unresectable, advanced and/or metastatic non-small cell lung cancer.
- Trial name
- NCT00701558
- Testing
- Erlotinib, Gemcitabine
- Where
- Romania
- Volunteers
- 20 people
- Sponsor
- Hoffmann-La Roche
Non-Small Cell Lung Cancer
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer With Asymptomatic Untreated Brain Metastasis
This study will assess the efficacy and safety of Avastin combined with first li ne paclitaxel-carboplatin (cohort 1) or second line Tarceva (cohort 2) in patien ts with non-squamous non-small cell lung cancer with asymptomatic…
- Trial name
- NCT00800202
- Testing
- bevacizumab [Avastin], carboplatin, erlotinib [Tarceva]
- Where
- 25 sites in France
- Volunteers
- 91 people
- Sponsor
- Hoffmann-La Roche
Prostatic Neoplasms
177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer
The purpose of this study is to determine whether 177Lu-PSMA-617 improves the Radiographic progression-free survival (rPFS) or Overall Survival (OS) compared to a change in Androgen receptor-directed therapy (ARDT) in metastatic…
- Trial name
- PSMAfore (NCT04689828)
- Testing
- 177Lu-PSMA-617, 68Ga-PSMA-11, ARDT
- Where
- 72 sites in United States, Austria and 12 more
- Volunteers
- 469 people
- Sponsor
- Novartis Pharmaceuticals
Secondary Progressive Multiple Sclerosis
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis
This is a Phase 3b, multicenter, international study conducted in 2 parts. Upon completion of the placebo-controlled period (Part 1), participants will have the option of enrolling in a 2-year open-label extension (Part 2).
- Trial name
- ASCEND in SPMS (NCT01416181)
- Testing
- natalizumab
- Where
- 161 sites in United States, Belgium and 15 more
- Volunteers
- 889 people
- Sponsor
- Biogen
Renal Cell Cancer
A Study of Avastin (Bevacizumab) in Combination With Low-Dose-Interferon in Patients With Metastatic Clear Cell Renal Cell Carcinoma (RCC).
This single arm study will assess progression free survival, tumor response and safety of Avastin in combination with interferon alfa-2a (IFN) as first line treatment in patients with metastatic clear cell renal cell carcinoma.
- Trial name
- NCT00796757
- Testing
- bevacizumab [Avastin], interferon alfa-2a
- Where
- 50 sites in Czechia, Estonia and 10 more
- Volunteers
- 146 people
- Sponsor
- Hoffmann-La Roche